Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen general counsel resigns
Bucknum’s sudden departure comes shortly after a sale of company stock which, according to Biogen Idec’s regulatory filings, made Bucknum a tidy profit of around $1.9 million. Biogen
Bucknum’s sudden departure comes shortly after a sale of company stock which, according to Biogen Idec’s regulatory filings, made Bucknum a tidy profit of around $1.9 million. Biogen
The positive effects seen with once-daily Agilect (rasagiline tablets) were similar to those seen in patients treated with entacapone, given with each levodopa dose, when compared to placebo.
In a letter to acting FDA commissioner Lester Crawford, the groups said the agency failed to comply with the Federal Advisory Committee Act (FACA) when it assigned scientists
Trimeris reported a net loss for the fourth quarter of 2004 of $5.7 million, compared with a loss of $8.3 million in the third quarter of 2004, and
The FDA public health advisory has advised healthcare professionals to prescribe Elidel (pimecrolimus) and Protopic (tacrolimus) only as directed and only after other eczema treatments have failed to
Opioids are often used in combination with other analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) in particular. With the discovery of an increased risk of cardiovascular events affecting popular COX-2
The VI Technologies (Vitex) shareholders also approved all other resolutions related to the merger, including the issuance of shares and warrants as part of a $20 million private
The primary objective of the phase II clinical trial was to compare the speed of absorption of ibuprofen into the bloodstream of a 400mg dose of ZAG-1701 with
New Mexican regulatory policies require that any advertising making medical claims must have prior approval from the Mexican national regulator, explained Biotech Holdings’ president and director, Robert Rieveley.
The $3.1 million phase II small business innovation research (SBIR) grant supplements the $1 million awarded to Vical in 2004 for the cytomegalovirus (CMV) vaccine program under two